GlassScriptPhysician profile
David Weissberger
NPI 1235179573
$6,485.79
in general payments reported to CMS, 2019-2025
32 companies · $1,889 in 2025
The $1,889 reported for 2025 was more than what 75% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $573 · 2020: $310 · 2021: $669 · 2022: $371 · 2023: $1,289 · 2024: $1,385 · 2025: $1,889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,358 · Education: $204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,358.12 |
| Education | $204.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,949.95 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $1,220.57 | 2021-2025 | Fasenra, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $465.63 | 2020-2025 | Ofev, Jascayd |
| Inogen, INC. | $306.25 | 2022-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Takeda Pharmaceuticals U.S.A., INC. | $275.39 | 2021-2025 | Glassia |
| United Therapeutics Corporation | $262.08 | 2021-2024 | Tyvaso |
| Insmed, INC. | $251.32 | 2019-2025 | Arikayce, Brinsupri |
| Grifols USA, LLC | $234.28 | 2020-2025 | Prolastin-C Liquid |
| Mallinckrodt Hospital Products INC. | $232.33 | 2023-2025 | Acthar |
| Regeneron Healthcare Solutions, INC. | $178.40 | 2019-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $124.39 | 2023-2024 | Opsumit, Uptravi |
| Inspire Medical Systems, INC. | $112.84 | 2021 | |
| Axsome Therapeutics, INC. | $101.57 | 2023-2025 | Sunosi |
| Ani Pharmaceuticals, INC. | $84.87 | 2024-2025 | Purified Cortrophin Gel |
| Genzyme Corporation | $69.32 | 2023-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $65.50 | 2024 | Yupelri |
| Verona Pharma, INC. | $62.17 | 2025 | Ohtuvayre |
| Amgen INC. | $59.92 | 2024-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $53.17 | 2025 | |
| Merck Sharp & Dohme LLC | $43.14 | 2024-2025 | Winrevair, Keytruda |
| Harmony Biosciences LLC | $42.06 | 2023 | Wakix |
| Genentech USA, INC. | $39.95 | 2019 | |
| Vifor Pharma, INC. | $39.56 | 2025 | Zemaira |
| Ethicon INC. | $37.40 | 2020-2021 | |
| Ambu INC. | $30.33 | 2024 | |
| Resmed Corp | $29.98 | 2023 | |
| Baxter Healthcare | $21.26 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Covis Pharma Gmbh | $20.51 | 2022 | |
| Tactile Systems Technology INC | $18.36 | 2025 | Nimbl, Flexitouch Plus |
| Abbvie INC. | $18.19 | 2021 | |
| Shire North American Group INC | $17.83 | 2019 | |
| Apria Healthcare LLC | $17.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Weissberger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.